EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity

Mateusz Kciuk iD, Adrianna Gielecińska iD, Somdutt Mujwar iD, Damian Kołat iD, Żaneta Kałuzińska-Kołat iD, Ismail Celik iD, Renata Kontek iD

Cells · 19.02.2023 · 12 (4) · 659

DOI: 10.3390/cells12040659 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 19.02.2023. Verfasst von Mateusz Kciuk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland. Hauptthemen laut MEDLINE: Doxorubicin, Neoplasms. Die Arbeit wurde bisher 845-mal zitiert (Crossref) und nennt 278 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX’s action are not fully understood. Emerging evidence points to the pleiotropic anticancer activity of DOX, including its contribution to DNA damage, reactive oxygen species (ROS) production, apoptosis, senescence, autophagy, ferroptosis, and pyroptosis induction, as well as its immunomodulatory role. This review aims to collect information on the anticancer mechanisms of DOX as well as its influence on anti-tumor immune response, providing a rationale behind the importance of DOX in modern cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinNeoplasmsHumansApoptosisReactive Oxygen SpeciesAutophagy

Stichwörter der Autor:innen

DNA damage response (DDR)adriamycinapoptosisdoxorubicinimmunotherapy

Substanzen

DoxorubicinReactive Oxygen Species

Autor:innen und Institutionen

  • Department of Molecular Biotechnology and Genetics, University of Lodz, 90-237 Lodz, Poland.
  • Doctoral School of Exact and Natural Sciences, University of Lodz, 90-237 Lodz, Poland.
  • Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India.
  • Department of Experimental Surgery, Faculty of Medicine, Medical University of Lodz, 90-136 Lodz, Poland.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Erciyes University, 38039 Kayseri, Turkey.

ORCID-Profile: Mateusz Kciuk, Adrianna Gielecińska, Somdutt Mujwar, Damian Kołat, Żaneta Kałuzińska-Kołat, Ismail Celik, Renata Kontek

Zitieren

APA

Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023). Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity. Cells, 12(4), 659. https://doi.org/10.3390/cells12040659

Vancouver

Kciuk M, Gielecińska A, Mujwar S, Kołat D, Kałuzińska-Kołat Ż, Celik I, et al. Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity. Cells. 2023;12(4):659. doi:10.3390/cells12040659

BibTeX
@article{Kciuk2023,
  author = {Kciuk, Mateusz and Gielecińska, Adrianna and Mujwar, Somdutt and Kołat, Damian and Kałuzińska-Kołat, Żaneta and Celik, Ismail and Kontek, Renata},
  title = {Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity},
  journal = {Cells},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {659},
  doi = {10.3390/cells12040659}
}
Kostenlos starten →